Drug Profile


Alternative Names: Rolapitant hydrochloride; SCH-619734; VARUBI; Varuby

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; Schering-Plough; TESARO
  • Class Antiemetics; Ethers; Piperidines; Pyrrolidines; Small molecules; Spiro compounds
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting
  • Discontinued Cough; Postoperative nausea and vomiting

Most Recent Events

  • 23 Feb 2017 CHMP recommends approval of rolapitant for Chemotherapy induced nausea and vomiting (Combination therapy, Prevention) in European Union
  • 11 Jan 2017 TESARO receives complete response letter from the FDA for rolapitant in Chemotherapy induced nausea and vomiting (IV)
  • 07 Oct 2016 Pooled efficacy data from the HEC 1, HEC 2 and MEC trials in Chemotherapy induced nausea and vomiting (In adults, In the elderly) presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top